Please assess the completion status of the following clinical trial:

Trial Title: An Open Label Study of Romiplostim in Adult Thrombocytopenic Subjects With ITP

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subject is ≥ 18 years of age~* Subject has a diagnosis of immune (idiopathic) thrombocytopenic purpura per the American Society of Hematology guidelines~* If Subject is \> 60 years of age, subject has a written bone marrow aspiration and/or biopsy report consistent with a diagnosis of ITP~* Subject has received at least 1 prior therapy for ITP~* Subject's platelet count is ≤ 30,000 or the subject is experiencing bleeding that is uncontrolled with conventional therapies~* Subject (or legally-acceptable representative) is willing and able to provide written informed consent~Exclusion Criteria:~* Subject has a history of hematological malignancy, myeloproliferative disorder, myelodysplastic syndrome (MDS), or bone marrow stem cell disorder~* Subject has participated in any study evaluating PEG-rHuMGDF, recombinant human thrombopoietin (rHuTPO), or related platelet product~* Subject has a known hypersensitivity to any recombinant E coli-derived product~* Subject has received any therapeutic drug or device that is not approved by the local regulatory health agency for any indication within 4 weeks of Screening~* Subject is of reproductive potential and is not using adequate contraceptive precautions, in the judgment of the investigator~* Subject is pregnant or breast feeding~* Investigator has concerns regarding the subject's ability to comply with the protocol procedures

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Romiplostim

Based on this trial design, predict the completion outcome and termination type (if applicable).